[DDS and Me].
With the success of the human genome project, the focus of life science research has shifted to the functional and structural analyses of proteins, such as proteomics and structural genomics. These analyses of proteins including newly identified proteins are expected to contribute to the identification of therapeutically applicable proteins for various diseases. Thus, pharmaco-proteomic-based drug discovery and development for protein therapies, including gene therapy, cell therapy, and vaccine therapy, is attracting current attention. However, there is clinical difficulty in using almost all bioactive proteins, because of their very low stability and pleiotropic actions in vivo. To promote pharmaco-proteomic-based drug discovery and development, we have attempted to develop drug delivery systems (DDSs), such as the protein-drug innovation system and the optimal cell therapeutic system. In this review, we introduce our original DDSs.
Mayumi
Tadanori
T
Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Japan. mayumi@pharm.kobegakuin.ac.jp
D000818:Animals; D064987:Cell- and Tissue-Based Therapy; D019020:Directed Molecular Evolution; D016503:Drug Delivery Systems; D015316:Genetic Therapy; D006801:Humans; D036103:Nanotechnology; D040901:Proteomics; D014612:Vaccines
D014612:Vaccines